Prolias announced a strategic acquisition of technology from the University of Maryland Biotechnology Institute (UMBI)
ROCKVILLE, MA, USA | January 7, 2010 | Prolias, a biotechnology company working to discover and develop novel therapeutic proteins and antibodies for treatment of disease, today announced a strategic acquisition of technology from the University of Maryland Biotechnology Institute (UMBI). The new technology will extend Prolias’ discovery platform, FIoNATM, by providing a platform for the creation of fully human, recombinant antibodies from diverse, endogenous antibody sources.
Dr. Jonathan Gottlieb, Director of Technology Transfer and Commercialization at UMBI, stated, “In the realm of antibody therapeutics, fully human antibodies are the preferable modality. This novel approach offers an alternative to phage libraries.” Joe Hernandez, Chairman of Prolias, stated “This acquisition gives Prolias access to a method of developing full human antibodies to the novel targets we have discovered via our existing FioNA technology. This provides us with the ability to discover new targets and develop antibodies to those targets in a seamless manner.”
The newly acquired technology, developed by Dr. George Lewis and colleagues at UMBI, provides Prolias with the means to generate fully human antibodies from naïve B cells in vitro. Advantages of the in vitro system are that it generates fully human antibodies without direct immunization of any patient or human individual, and antibodies can be created from readily accessible tissues such as human peripheral blood.
About Prolias
Prolias is a privately held biotechnology company dedicated to the discovery and development of novel therapeutic proteins using proprietary FIoNATM and Bead BlotTM technologies. Prolias is developing ligand based affinity resins to purify proteins quickly from a variety of biological samples including whole blood. Prolias also offers a variety of ELISA kits and recombinant proteins for research based purposes. Additional information is available at www.proliastechnologies.com
SOURCE: Prolias
Post Views: 48
Prolias announced a strategic acquisition of technology from the University of Maryland Biotechnology Institute (UMBI)
ROCKVILLE, MA, USA | January 7, 2010 | Prolias, a biotechnology company working to discover and develop novel therapeutic proteins and antibodies for treatment of disease, today announced a strategic acquisition of technology from the University of Maryland Biotechnology Institute (UMBI). The new technology will extend Prolias’ discovery platform, FIoNATM, by providing a platform for the creation of fully human, recombinant antibodies from diverse, endogenous antibody sources.
Dr. Jonathan Gottlieb, Director of Technology Transfer and Commercialization at UMBI, stated, “In the realm of antibody therapeutics, fully human antibodies are the preferable modality. This novel approach offers an alternative to phage libraries.” Joe Hernandez, Chairman of Prolias, stated “This acquisition gives Prolias access to a method of developing full human antibodies to the novel targets we have discovered via our existing FioNA technology. This provides us with the ability to discover new targets and develop antibodies to those targets in a seamless manner.”
The newly acquired technology, developed by Dr. George Lewis and colleagues at UMBI, provides Prolias with the means to generate fully human antibodies from naïve B cells in vitro. Advantages of the in vitro system are that it generates fully human antibodies without direct immunization of any patient or human individual, and antibodies can be created from readily accessible tissues such as human peripheral blood.
About Prolias
Prolias is a privately held biotechnology company dedicated to the discovery and development of novel therapeutic proteins using proprietary FIoNATM and Bead BlotTM technologies. Prolias is developing ligand based affinity resins to purify proteins quickly from a variety of biological samples including whole blood. Prolias also offers a variety of ELISA kits and recombinant proteins for research based purposes. Additional information is available at www.proliastechnologies.com
SOURCE: Prolias
Post Views: 48
